Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Spiroperidol
2. Spiroperone
1. Spiropitan
2. Spiroperidol
3. 749-02-0
4. Espiperona
5. Spiperonum
6. R 5147
7. [3h]spiperone
8. [3h]-spiperone
9. 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
10. E 525
11. Nsc 170983
12. Mls000028615
13. Spiroperidol;r-5147
14. 8-(3-(p-fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(4.5)decan-4-one
15. 8-(3-p-fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane
16. Nsc-170983
17. Smr000058674
18. 1,3,8-triazaspiro(4.5)decan-4-one, 8-(4-(4-fluorophenyl)-4-oxobutyl)-1-phenyl-
19. 4x6e73cj0q
20. Chebi:9233
21. Chembl267930
22. R-5147
23. Butyrophenone, 4'-fluoro-4-(4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decan-8-yl)-
24. Nsc170983
25. Ncgc00015964-09
26. Cas-749-02-0
27. 1,3,8-triazaspiro(4.5)decan-4-one, 8-(3-(p-fluorobenzoyl)propyl)-1-phenyl-
28. 1,3,8-triazaspiro[4.5]decan-4-one, 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-
29. 8-(4-(4-fluorophenyl)-4-oxobutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
30. 8-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
31. Dsstox_cid_25205
32. Dsstox_rid_80749
33. Dsstox_gsid_45205
34. Spiroperidone
35. Spiperonum [inn-latin]
36. Espiperona [inn-spanish]
37. 1,3,8-triazaspiro[4.5]decan-4-one, 8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-
38. 8-[4-(4-fluorophenyl)-4-oxo-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
39. Spiperone [usan:inn:ban:jan]
40. Einecs 212-024-0
41. Brn 0632204
42. Unii-4x6e73cj0q
43. Sr-01000000261
44. Spiperone, Solid
45. Spiropitan (tn)
46. Prestwick_624
47. [3h]-spiroperidol
48. Spectrum_001143
49. Tocris-0995
50. Spiperone [inn]
51. Spiperone [jan]
52. Spiperone [mi]
53. Spiperone (jan/usan)
54. Regid855701
55. Spiperone [usan]
56. Opera_id_1551
57. Prestwick0_000288
58. Prestwick1_000288
59. Prestwick2_000288
60. Prestwick3_000288
61. Spectrum2_001426
62. Spectrum3_001460
63. Spectrum4_000451
64. Spectrum5_000987
65. Lopac-s-7395
66. Gtpl99
67. Spiperone [mart.]
68. 4-phenyl-8-[3-(4-fluorobenzoyl)propyl]-1-oxo-2,4,8-triazaspiro[4,5]decane
69. Cid_5265
70. Spiperone [who-dd]
71. Lopac0_001069
72. Regid_for_cid_5265
73. Bspbio_000196
74. Bspbio_002959
75. Kbiogr_000862
76. Kbioss_001623
77. Mls001076321
78. Divk1c_000566
79. Schembl116031
80. Spectrum1501152
81. Spbio_001532
82. Spbio_002415
83. Bpbio1_000216
84. Gtpl3300
85. Dtxsid5045205
86. Bdbm21397
87. Hms501m08
88. Kbio1_000566
89. Kbio2_001623
90. Kbio2_004191
91. Kbio2_006759
92. Kbio3_002459
93. Tqp0726
94. Ninds_000566
95. Hms1568j18
96. Hms1921l09
97. Hms2089e16
98. Hms2092h17
99. Hms2095j18
100. Hms2235e11
101. Hms3371l01
102. Hms3712j18
103. Pharmakon1600-01501152
104. Zinc643233
105. Hy-b1371
106. Tox21_110269
107. Ccg-38975
108. Nsc757864
109. Akos024282958
110. Tox21_110269_1
111. Nsc-757864
112. Sdccgsbi-0051039.p004
113. Idi1_000566
114. Ncgc00015964-01
115. Ncgc00015964-02
116. Ncgc00015964-03
117. Ncgc00015964-04
118. Ncgc00015964-05
119. Ncgc00015964-06
120. Ncgc00015964-07
121. Ncgc00015964-08
122. Ncgc00015964-10
123. Ncgc00015964-11
124. Ncgc00015964-12
125. Ncgc00015964-13
126. Ncgc00015964-17
127. Ncgc00015964-25
128. Ncgc00016536-01
129. Ncgc00022260-02
130. Ncgc00022260-04
131. Ncgc00022260-05
132. Ncgc00022260-06
133. Ncgc00022260-07
134. Sbi-0051039.p003
135. Ab00052224
136. Cs-0013110
137. Ft-0674639
138. D01051
139. Ab00052224-15
140. Ab00052224_16
141. L000569
142. Q3077150
143. Sr-01000000261-5
144. Sr-01000000261-8
145. Brd-k55468218-001-05-5
146. Brd-k55468218-003-01-0
147. Wln: T6n Dxtj A3vr Df& D-& Ct5mvxn Ehj Dr
148. 8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-1,8-triazaspiro[4.5]decan-4-one
149. 1,8-triazaspiro[4.5]decan-4-one, 8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-
150. 1,8-triazaspiro[4.5]decan-4-one, 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-
151. 8-[4-(4-fluorophenyl)-4-keto-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
152. 8-[4-(4-fluorophenyl)-4-oxo-butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one
153. 1-(4-fluorophenyl)-4-(4-hydroxy-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-en-8-yl)-1-butanone #
154. Sip
| Molecular Weight | 395.5 g/mol |
|---|---|
| Molecular Formula | C23H26FN3O2 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 395.20090524 g/mol |
| Monoisotopic Mass | 395.20090524 g/mol |
| Topological Polar Surface Area | 52.6 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 577 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
ABOUT THIS PAGE
54
PharmaCompass offers a list of Spiperone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Spiperone manufacturer or Spiperone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Spiperone manufacturer or Spiperone supplier.
PharmaCompass also assists you with knowing the Spiperone API Price utilized in the formulation of products. Spiperone API Price is not always fixed or binding as the Spiperone Price is obtained through a variety of data sources. The Spiperone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A E 525 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of E 525, including repackagers and relabelers. The FDA regulates E 525 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. E 525 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A E 525 supplier is an individual or a company that provides E 525 active pharmaceutical ingredient (API) or E 525 finished formulations upon request. The E 525 suppliers may include E 525 API manufacturers, exporters, distributors and traders.
E 525 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of E 525 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right E 525 GMP manufacturer or E 525 GMP API supplier for your needs.
A E 525 CoA (Certificate of Analysis) is a formal document that attests to E 525's compliance with E 525 specifications and serves as a tool for batch-level quality control.
E 525 CoA mostly includes findings from lab analyses of a specific batch. For each E 525 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
E 525 may be tested according to a variety of international standards, such as European Pharmacopoeia (E 525 EP), E 525 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (E 525 USP).
